Skip to content
  • Antibodies & Bispecifics
    • Antibody Platforms
    • Monoclonal Discovery
    • Bispecific Discovery
    • Optimization
  • TCR Mimics
  • Genetic Medicines
  • Cell Therapies
  • Partnering
    • Ecosystem Allies
  • About
    • Leadership
    • News and Events
    • Careers
    • Resources
  • Antibodies & Bispecifics
    • Antibody Platforms
    • Monoclonal Discovery
    • Bispecific Discovery
    • Optimization
  • TCR Mimics
  • Genetic Medicines
  • Cell Therapies
  • Partnering
    • Ecosystem Allies
  • About
    • Leadership
    • News and Events
    • Careers
    • Resources
Contact Us

Type: Press Releases

Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic Diseases

Maze Therapeutics and Alloy Therapeutics announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases.

← Previous
Contact Us

Democratizing access to foundational biologics discovery technologies & services.

Contact

@alloy-therapeutics-inc

info@alloytx.com

275 Second Ave, Suite 200, Waltham, MA 02451

Modalities

  • Antibodies & Bispecifics
  • TCR Mimics
  • Genetic Medicines
  • Cell Therapies

Ecosystem

  • Partnering
  • Ecosystem Allies

Company

  • About
  • Leadership
  • Careers

Insights

  • Resources
  • News & Events

© 2025 Alloy Therapeutics, Inc. All Rights Reserved. 

Privacy Policy | Terms & Conditions